The effect of SETD2 mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4583-4583
10.1200/jco.2014.32.15_suppl.4583